Why OncoMed Pharmaceuticals, Unilife, and Tesla Motors Are Today's 3 Best Stocks

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

Despite another month of incredible strong U.S. auto sales figures, the broad-based S&P 500 couldn't mount a comeback and ended the day lower for a third straight session.

There were two primary factors weighing down the S&P 500 today. First, the endless uptrend in the S&P 500 has investors concerned that the Federal Reserve may taper its monthly bond-buying stimulus known as QE3 earlier than expected, which means less "free money" being added to the market and the potential for higher interest rates. Once again, it's a bit of a Catch-22, where a good market environment means the end of the Fed's ongoing stimulus, while bad economic news gets cheers from the crowd because QE3 will continue.

The other factor pushing the iconic index lower was weakness in the consumer-goods sector. Initial estimates from Black Friday show a huge boost for direct-to-consumer-based sales while bricks-and-mortar companies saw lower-priced and deeply discounted items flying off their shelves. Overall, this reinforces the trend we saw during the back-to-school season that it's going to be a tough holiday season for retailers.

U.S. auto sales, though, were the one bright spot. General Motors, Ford, and Chrysler reported year-over-year November unit sale increases of 13.9%, 7.1% and 16%, respectively, while Honda Motor actually reported a slight dip in sales. As has been the case, GM's redesigned Silverado and Sierra continue to fuel sales while Ford is cruising in the fuel-efficient compact car category. Furthermore, the industry is on pace to sell more than 16 million seasonally adjusted units, which is its highest level since before the recession.

By day's end, the S&P 500 finished lower by 5.75 points (-0.32%) to close at 1,795.15, which is still less than 1% from a new all-time high.

Topping the charts to the upside was OncoMed Pharmaceuticals (NASDAQ: OMED  ) , which spiked higher by as much as 126% at one point after striking a collaborative agreement with Celgene (NASDAQ: CELG  ) to develop up to six cancer stem cell therapies. The deal involves Celgene paying OncoMed $155 million upfront, making a $22.5 million investment in OncoMed's common stock, and could net OncoMed billions in milestone payments. Based on its press release, OncoMed could earn up to $790 million in milestones for its lead drug, demcizumab, an additional $505 million for an anti-DLL4/VEGF bispecific antibody, and up to $440 million for four additional anti-CSC therapies, each. If OncoMed shareholders had any fears of running out of cash anytime soon, those are now gone. Shares ended the day higher by 97.9%.

Continuing the theme of striking deals, Unilife (NASDAQ: UNIS  ) , which makes injectable drug delivery systems, rose 16.6% after striking a deal with Novartis (NYSE: NVS  ) to supply clinical products from one of its injectable drug delivery systems for one of Novartis' early stage clinical compounds. The deal nets Unilife milestone payments totaling $15 million, and it can earn additional royalties on sales of the syringes. In addition, Novartis may extend the deal to 2024. This marks the second commercial deal for Unilife in just the past month and has put the company on the path toward shrinking its cash burn and possibly being profitable as early as next year.

Finally, electric-vehicle maker Tesla Motors (NASDAQ: TSLA  ) rallied 16.5% after the Federal Motor Transport Authority in Germany cleared Tesla's Model S of any manufacturing defects following a series of three fires in a matter of six weeks. The National Highway Traffic Safety Administration in the U.S. has yet to release its findings, but chances are good that Tesla shares could rally further if the NHTSA finds no defects with the Model S as well. As for me, I remain short shares of Tesla Motors, as I find the valuation on a per-car basis, the series of missed building deadlines, the high-cost and uncertainty of a production ramp-up, and a lack of EV long-range infrastructure, to be a deterrent to its frothy share price.

Could this company be the next big gainer?
The market stormed out to huge gains across 2013, leaving investors on the sidelines burned. However, opportunistic investors can still find huge winners. The Motley Fool's chief investment officer has just hand-picked one such opportunity in our new report: "The Motley Fool's Top Stock for 2014." To find out which stock it is and read our in-depth report, simply click here. It's free!

Read/Post Comments (4) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On December 03, 2013, at 5:50 PM, LKuo1 wrote:

    According to the article, TSLA can go up further; yet author claims still shorting stock.

    What gives?-does it may sense?!

  • Report this Comment On December 03, 2013, at 11:04 PM, djtetsu wrote:

    Oh the guy who thought Tim Cook was the 3rd worst CEO..

    They are not the BEST by any means.

    You simply need to quit contributing.

  • Report this Comment On December 04, 2013, at 2:58 AM, SamA wrote:

    The deal terms you mentioned for Novartis and Unilife - extension upto 2024, and $15 million in payments - these are the terms of Sanofi deal. The details of Novartis deal have been kept confidential, as of yet, as far as I know.

  • Report this Comment On December 04, 2013, at 3:29 AM, LookAtFacts wrote:

    I don't think it is contradictory to say short term the stock may rise and still be short. Momentum stocks are frequently overvalued and may react at very short notice, besides we don't know at what price the author shorted TSLA. Maybe he sold it at $190 and believes long term it will drop to his perceived fair value. He could cover and re-short but that is clearly not his long term strategy. I won't be surprised to see TSLA drop a bit tomorrow and then rise again once the NHTSA gives them a clean bill of health. Since that report is not due before January, TSLA has until Jan 2, to respond. Also maybe the author is a long term trader and doesn't believe in timing the market. I have shorted shock before and don't react to every short term move.

    Since I am new to this author I don't carry any past data so I can only judge him on this article. Maybe with your history you could be right

Add your comment.

DocumentId: 2750942, ~/Articles/ArticleHandler.aspx, 4/19/2014 2:10:31 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...